0001193125-24-134767.txt : 20240509 0001193125-24-134767.hdr.sgml : 20240509 20240509073706 ACCESSION NUMBER: 0001193125-24-134767 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240509 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sensei Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001829802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39980 FILM NUMBER: 24928606 BUSINESS ADDRESS: STREET 1: 1405 RESEARCH BLVD, SUITE 125 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: (240) 243-8000 MAIL ADDRESS: STREET 1: 1405 RESEARCH BLVD, SUITE 125 CITY: ROCKVILLE STATE: MD ZIP: 20850 8-K 1 d836832d8k.htm 8-K 8-K
false 0001829802 0001829802 2024-05-09 2024-05-09 0001829802 us-gaap:CommonStockMember 2024-05-09 2024-05-09 0001829802 us-gaap:SeriesAPreferredStockMember 2024-05-09 2024-05-09

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 9, 2024

 

 

Sensei Biotherapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-39980   83-1863385

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

1405 Research Blvd, Suite 125

Rockville, MD

   20850
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (240) 243-8000

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

 

Title of each class

  

Trading

symbol

  

Name of each exchange

on which registered

Common Stock   SNSE   The Nasdaq Stock Market LLC
Series A Preferred Stock Purchase Rights     The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02

Results of Operations and Financial Condition.

On May 9, 2024, Sensei Biotherapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02 and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether filed before or after the date hereof and regardless of any general incorporation language in such filing.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
Number

   

Exhibit Description

99.1    Press Release of Sensei Biotherapeutics, Inc., dated May 9, 2024
104    The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      Sensei Biotherapeutics, Inc.
Date: May 9, 2024        

/s/ Christopher W. Gerry

      Christopher W. Gerry
      General Counsel and Secretary

 

3

EX-99.1 2 d836832dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

- Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities -

- Company to present topline clinical data from the SNS-101 Phase 1 dose escalation study at the 2024 ASCO Annual Meeting -

- Enrollment in the dose expansion portion of the clinical study advancing -

- Strong balance sheet with cash runway into fourth quarter of 2025 -

BOSTON, MA – May 09, 2024 – Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended March 31, 2024, and provided corporate updates.

“Building upon our initial data for SNS-101, which we believe support a favorable and potentially best-in-class clinical safety and PK profile, we now look forward to sharing topline dose escalation data at ASCO in June and initial dose expansion data in the fourth quarter of this year,” said John Celebi, President and Chief Executive Officer. “Looking ahead, we are squarely focused on advancing patient enrollment in the dose expansion cohorts, which are intended to generate additional supportive data and optimize the Phase 2 trial design for SNS-101. With cash runway into the fourth quarter of 2025, we believe we are in a strong position to build on both our clinical momentum on behalf of the patients we aim to serve and our scientific advances, as illustrated by our recent publication in Nature Communications.”

Highlights and Milestones

SNS-101

SNS-101 is a conditionally active antibody harnessing the acidic tumor microenvironment to selectively target the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation). VISTA is implicated in numerous cancer indications and its expression correlates with low survival rates. Sensei is conducting a multi-center Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101 as both a monotherapy and in combination with Regeneron’s PD-1 inhibitor Libtayo® (cemiplimab) in patients with advanced solid tumors. Recent updates include:

 

  •  

Sensei has completed enrollment in the dose escalation portion of the Phase 1/2 clinical trial of SNS-101, enrolling 16 patients in the monotherapy arm and 18 patients in the combination arm.

 

  •  

In the monotherapy dose escalation arm, patients have cleared all planned dosing cohorts of 0.3, 1, 3, 10, and 15 mg/kg.

  •  

In the combination dose escalation arm, patients have cleared all planned dosing cohorts of 3, 10, and 15 mg/kg of SNS-101 plus Libtayo.

 

  •  

There have been no dose limiting toxicities (DLT) observed across both the monotherapy and the combination arms.

 

  •  

Sensei will present topline clinical data from the monotherapy and combination dose escalation portion of its Phase 1/2 trial of SNS-101 in a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 31 – June 4, 2024.

 

  •  

Title: Initial results from a first-in-human phase 1 study of SNS-101 (pH-selective anti-VISTA antibody) alone or in combination with cemiplimab in patients with advanced solid tumors

 

  •  

Presenter: Dr. Shiraj Sen

 

  •  

Session Type: Poster Session

 

  •  

Session Title: Developmental Therapeutics—Immunotherapy

 

  •  

Date and Time: Saturday, June 1, 2024, at 9:00 a.m. – 12:00 p.m. CDT

 

  •  

Abstract Number: 2600

 

  •  

Patient enrollment is ongoing for both the monotherapy and combination dose expansion arms.

 

  •  

In the monotherapy dose expansion arm, Sensei is enrolling patients with microsatellite stable (MSS) colorectal cancer (CRC) at a dose level of 15 mg/kg.

 

  •  

In the combination dose expansion arm, Sensei is enrolling patients with MSS CRC, Head and Neck (H&N) cancer, non-small cell lung cancer (NSCLC), and melanoma at a dose level of 15 mg/kg plus Libtayo.

 

  •  

The solid tumor types were selected to focus the cancer indications on a basket of more commonly occurring histologies, including both “hot” (NSCLC, H&N, Melanoma) and “cold” (CRC) tumors where the company believes SNS-101 has potential to provide clinical benefit based on VISTA biology and supporting preclinical data. Additional tumor types and doses may be considered for both the monotherapy and combination expansion arms.

 

  •  

The Company expects to report initial data from the dose expansion cohorts and hold an end-of-Phase 1 meeting with the FDA by the end of 2024.

 

  •  

In April 2024, Sensei published a peer-reviewed research paper in Nature Communications describing the mechanism of action of SNS-101 selectively targeting the active form of VISTA within the tumor microenvironment.

 

  •  

In March 2024, the company presented SNS-101 data at Keystone Symposia’s Cancer Immunotherapy: Beyond Immune Checkpoint Blockade and Overcoming Resistance.

 

  •  

In February, Sensei presented at the 10th Annual Immuno-Oncology 360 Conference (IO360).

Corporate Updates

 

  •  

In January 2024, Sensei announced the appointment of Ron Weitzman, M.D., F.A.C.P., as part-time Chief Medical Officer.

 

  •  

In January 2024, Sensei announced a realignment of its resources to fully support the Phase 1/2 clinical trial of SNS-101. As a result, Sensei has paused IND-enabling work on its preclinical-stage TMAb programs, including SNS-102 (VSIG4), SNS-103 (CD39) and SNS-201 (VISTAxCD28). Preclinical work to characterize selected lead antibodies, including their mechanisms of action, and target biology is expected to continue throughout 2024.

  •  

As a result of this realignment of resources Sensei’s cash runway now extends into the fourth quarter of 2025.

First Quarter 2024 Financial Results

Cash Position: Cash, cash equivalents and marketable securities were $58.1 million as of March 31, 2024, as compared to $65.8 million as of December 31, 2023. The decrease is due to cash used to fund operations. Sensei expects its current cash balance to fund operations into the fourth quarter of 2025.

Research and Development (R&D) Expenses: R&D expenses were $4.9 million for the quarter ended March 31, 2024, compared to $5.2 million for the quarter ended March 31, 2023. The decrease in R&D expenses was primarily attributable to lower manufacturing-related expenses and lower costs related to preclinical research, primarily offset by higher expenses associated with clinical trials.

General and Administrative (G&A) Expenses: G&A expenses were $3.8 million for the quarter ended March 31, 2024, compared to $5.8 million for the quarter ended March 31, 2023. The decrease in G&A expense was primarily attributable to decreased cost for external professional services.

Net Loss: Net loss was $8.0 million for the quarter ended March 31, 2024, compared to $10.2 million for the quarter ended March 31, 2023.

About Sensei Biotherapeutics Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead product candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody consisting of a CD28 agonist arm and a pH-sensitive anti-VISTA arm. For more information, please visit www.senseibio.com, and follow the company on X @SenseiBio and LinkedIn.

Condensed Statements of Operations

(Unaudited, in thousands except share and per share data)

 

     Three Months Ended
March 31,		  
     2024      2023  

Operating expenses:

      

Research and development

    $ 4,917      $ 5,204  

General and administrative

      3,813        5,804  
  

 

 

     

 

 

  

Total operating expenses

      8,730        11,008  
  

 

 

     

 

 

  

Loss from operations

      (8,730 )       (11,008 ) 

Total other income

      738        831  

Net loss

      (7,992 )       (10,177 ) 
  

 

 

     

 

 

  

Net loss attributable to common stockholders

      (7,992 )       (10,177 ) 

Net loss per share, basic and diluted

    $ (0.32 )     $ (0.33 ) 
  

 

 

     

 

 

  

Weighted-average common shares outstanding, basic and diluted

      25,049,111        30,866,087  
  

 

 

     

 

 

  

Selected Condensed Balance Sheet Data

(Unaudited, in thousands)

 

     March 31,
2024		      December 31,
2023		  

Cash and cash equivalents

    $ 10,956      $ 13,011  

Marketable securities

      47,125        52,746  

Total assets

      66,695        74,374  

Total liabilities

      8,221        9,479  

Total stockholders’ equity

      58,474        64,895  

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “believe”, “designed to,” “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Sensei’s current beliefs and expectations. These forward-looking statements include expectations regarding the development and potential therapeutic benefits of Sensei’s product candidates, the timing of Sensei’s Phase 1/2 clinical trial of SNS-101, including reporting of data therefrom, the timing of preclinical R&D activities, and its belief that its existing cash and cash equivalents will be sufficient to fund its operations into the fourth quarter of 2025. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the development of therapeutic product candidates, such as the risk that any one or more of Sensei’s product candidates will not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of

Sensei’s product candidates; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Sensei’s product candidates; the risk that Sensei’s product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that Sensei anticipates; risks associated with Sensei’s dependence on third-party suppliers and manufacturers, including sole source suppliers, over which Sensei may not always have full control; risks regarding the accuracy of Sensei’s estimates of expenses, capital requirements and needs for additional financing; and other risks and uncertainties that are described in Sensei’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on May 9, 2024 and Sensei’s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Sensei as of the date of this release, and Sensei assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:

Michael Biega

Senior Director, Investor Relations

Sensei Biotherapeutics

mbiega@senseibio.com

Media Contact:

Joyce Allaire

LifeSci Advisors

Jallaire@lifesciadvisors.com

 EX-101.SCH 3 snse-20240509.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 4 snse-20240509_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 snse-20240509_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock [Member] Common Stock [Member] Series A Preferred Stock [Member] Series A Preferred Stock [Member] EX-101.PRE 6 snse-20240509_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document and Entity Information
May 09, 2024
Document And Entity Information [Line Items]  
Amendment Flag false
Entity Central Index Key 0001829802
Document Type 8-K
Document Period End Date May 09, 2024
Entity Registrant Name Sensei Biotherapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39980
Entity Tax Identification Number 83-1863385
Entity Address, Address Line One 1405 Research Blvd
Entity Address, Address Line Two Suite 125
Entity Address, City or Town Rockville
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20850
City Area Code (240)
Local Phone Number 243-8000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Common Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Common Stock
Trading Symbol SNSE
Security Exchange Name NASDAQ
Series A Preferred Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Series A Preferred Stock Purchase Rights
Security Exchange Name NASDAQ
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 3 24 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [dq-60546-SecurityExchangeName-TradingSymbol, NoTradingSymbolFlag-Dependency] In submission type 8-K, SecurityExchangeName should have a value if one of TradingSymbol, NoTradingSymbolFlag has a value in context duration_2024-05-09_to_2024-05-09_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember. d836832d8k.htm 78 d836832d8k.htm snse-20240509.xsd snse-20240509_def.xml snse-20240509_lab.xml snse-20240509_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d836832d8k.htm": { "nsprefix": "snse", "nsuri": "http://senseibio.com/20240509", "dts": { "inline": { "local": [ "d836832d8k.htm" ] }, "schema": { "local": [ "snse-20240509.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "definitionLink": { "local": [ "snse-20240509_def.xml" ] }, "labelLink": { "local": [ "snse-20240509_lab.xml" ] }, "presentationLink": { "local": [ "snse-20240509_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 2, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 31, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-05-09_to_2024-05-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d836832d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-05-09_to_2024-05-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d836832d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "snse_DocumentAndEntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://senseibio.com/20240509", "localname": "DocumentAndEntityInformationLineItems", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "auth_ref": [] }, "snse_DocumentAndEntityInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://senseibio.com/20240509", "localname": "DocumentAndEntityInformationTable", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock [Member]" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://senseibio.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001193125-24-134767-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-134767-xbrl.zip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end XML 19 d836832d8k_htm.xml IDEA: XBRL DOCUMENT 0001829802 2024-05-09 2024-05-09 0001829802 us-gaap:CommonStockMember 2024-05-09 2024-05-09 0001829802 us-gaap:SeriesAPreferredStockMember 2024-05-09 2024-05-09 false 0001829802 8-K 2024-05-09 Sensei Biotherapeutics, Inc. DE 001-39980 83-1863385 1405 Research Blvd Suite 125 Rockville MD 20850 (240) 243-8000 false false false false Common Stock SNSE NASDAQ Series A Preferred Stock Purchase Rights NASDAQ true false